Mechanistic Clinical Award

Mechanistic Clinical Award

Administers pilot clinical studies pairing lifestyle interventions with mechanistic analysis through the Mechanistic Clinical Award.

The Mechanistic Clinical Award is a grant program of the Lupus Research Alliance (LRA) that supports pilot clinical studies testing lifestyle interventions in lupus patients, paired with hypothesis-driven mechanistic analysis to understand the biological effects of those interventions. The LRA, headquartered in New York and operating under Federal Tax ID #58-2492929, has distributed over $284 million across more than 675 grants and directs 100% of donated funds to research. This award was established to fill a specific gap: creating a nimbler clinical testing framework for lifestyle-based strategies that have shown theoretical promise but lacked rigorous mechanistic investigation in lupus populations.

The award provides $750,000 for up to three years. Eligible intervention areas include physical activity and exercise, diet and nutrition, mental health, harmful exposure prevention such as sun exposure, smoking, and alcohol, sleep, and social relation-based interventions. All funded projects must combine a testable clinical intervention with a mechanistic hypothesis — studies without a clear mechanistic component are out of scope. Eligible applicants are universities and nonprofit research institutions; for-profit entities are not eligible. The 2026 cycle deadline has passed; the 2027 cycle is anticipated. Scientific questions go to Kari Fischer, PhD, at kfischer@lupusresearch.org, and administrative inquiries to Diomaris Gonzalez at dgonzalez@lupusresearch.org.

For clinical researchers working at the intersection of lifestyle medicine and autoimmunity, the Mechanistic Clinical Award provides meaningful resources — $750K over three years — to conduct a well-powered pilot study with integrated biomarker or immunological endpoints. Successful proposals will combine a clearly defined patient population, a feasible intervention protocol, and a mechanistic hypothesis grounded in lupus biology. The LRA's broader 2024–2028 strategy emphasizes personalized treatments and patient-centered outcomes, so applications that connect lifestyle findings to disease stratification or precision medicine will be well aligned.